How to Get Zetia (Ezetimibe) in Louisiana

What Zetia (Ezetimibe) Is and Why Louisiana Patients Use It

Zetia is a prescription cholesterol-absorption inhibitor approved by the FDA in 2002 for lowering low-density lipoprotein cholesterol (LDL-C) as an adjunct to diet, either alone or with a statin [1]. Ezetimibe blocks the Niemann-Pick C1-like 1 (NPC1L1) protein in the small intestinal brush border, reducing dietary and biliary cholesterol absorption by roughly 54% [2]. The drug does not require dose titration; a single 10 mg tablet taken once daily is the only approved dose [1].

Louisianans carry one of the highest cardiovascular disease burdens in the United States. The CDC reports that Louisiana's age-adjusted heart disease death rate exceeds the national average by approximately 15% [3]. That burden makes LDL-C control a clinical priority across the state, and ezetimibe is one of the guideline-recommended options when statins alone are insufficient or not tolerated [4].

The 2018 ACC/AHA cholesterol guideline states: "For patients with clinical ASCVD whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe therapy" [4]. Generic ezetimibe became available in the United States in 2017, which sharply reduced the cost barrier that had previously limited its use.

A 2019 analysis in JAMA Cardiology found that ezetimibe use in eligible post-ACS patients remained under 30% despite guideline recommendations, suggesting that access and awareness gaps persist nationally and in high-burden states like Louisiana [5].

Clinical Evidence Supporting Ezetimibe

The IMPROVE-IT trial, published in the New England Journal of Medicine in 2015, enrolled 18,144 patients stabilized after an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo [6]. Over a median 6-year follow-up, the combination group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo group. The primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group, an absolute risk reduction of 2.0 percentage points and a relative risk reduction of 6.4% (P<0.001) [6].

That trial established the "lower is better" principle for LDL-C and confirmed that non-statin add-on therapy produces cardiovascular benefit beyond statin therapy alone. The number needed to treat over 7 years was 50, a figure comparable to many widely accepted preventive interventions [6].

Ezetimibe also shows meaningful LDL-C reductions as monotherapy. A Cochrane systematic review of 26 randomized controlled trials found that ezetimibe monotherapy lowered LDL-C by a weighted mean of 18.6% compared with placebo [7]. When combined with a moderate-intensity statin, ezetimibe produces LDL-C reductions equivalent to doubling the statin dose, but without the dose-dependent myopathy risk [4].

The drug's safety record across more than two decades is well characterized. Rates of hepatotoxicity and myopathy in IMPROVE-IT were not statistically different between the ezetimibe and placebo groups [6]. The FDA label notes that ezetimibe is generally well tolerated, with the most common adverse effects being upper respiratory infection, diarrhea, and arthralgia [1].

Who Can Prescribe Zetia in Louisiana

Any Louisiana-licensed prescriber with authority to write controlled and non-controlled medications may prescribe ezetimibe. The drug is not a controlled substance, so prescribing authority is broad.

Specifically, the following practitioners are authorized:

Medical doctors (MDs) and osteopathic physicians (DOs) hold full prescriptive authority under Louisiana RS 37:1261 and may prescribe ezetimibe without restriction [8].

Nurse practitioners (NPs) in Louisiana operate under a collaborative practice agreement and hold prescriptive authority for non-controlled medications after completing 6 to 000 hours of supervised practice, per Louisiana RS 37:913 [9]. An NP working in cardiology, internal medicine, or a telehealth platform can prescribe Zetia.

Physician assistants (PAs) are licensed by the Louisiana State Board of Medical Examiners and may prescribe non-controlled drugs under a supervising physician's delegation [10].

This breadth of prescribing authority matters for telehealth access. A patient who cannot see a cardiologist for weeks may receive a same-day ezetimibe prescription from an NP or PA practicing via a licensed Louisiana telehealth platform.

Getting a Zetia Prescription Through Telehealth in Louisiana

Louisiana permits telehealth prescribing of non-controlled medications, including ezetimibe, under the Louisiana Telehealth Act (RS 40:1223.3) [11]. A clinician must conduct a good-faith evaluation of the patient before prescribing, but that evaluation may occur entirely via synchronous audio-video encounter. An existing clinical relationship with the prescriber is not required for the initial visit.

The typical telehealth process for ezetimibe in Louisiana runs as follows:

1. The patient schedules a same-day or next-day video visit with a licensed Louisiana telehealth provider.
2. Before or during the visit, the patient uploads recent lab work (lipid panel within the past 12 months is sufficient for most platforms; some accept up to 24 months).
3. The clinician reviews cardiovascular risk, current statin use, contraindications, and drug interactions.
4. If appropriate, the prescription is sent electronically to the patient's pharmacy of choice in Louisiana.
5. Most major retail pharmacies (Walgreens, CVS, Walmart, Brookshire's, Rouses) fill generic ezetimibe within two to four hours of receiving the electronic prescription.

Telehealth platforms operating in Louisiana and prescribing cardiovascular medications typically charge $50, $99 for an initial visit without insurance, though several accept commercial insurance for the consult fee. The visit itself does not require a physical exam; a history and lab review are clinically sufficient for ezetimibe initiation in most outpatient scenarios [4].

The HealthRX clinical team has identified the following decision framework for Louisiana telehealth ezetimibe initiation. Patients who meet all four criteria are typically appropriate for same-visit prescribing: (1) documented LDL-C of 70 mg/dL or higher on a lipid panel within 24 months; (2) established diagnosis of hyperlipidemia, ASCVD, or familial hypercholesterolemia; (3) no active hepatic disease or prior ezetimibe intolerance; and (4) concurrent statin use or a documented statin intolerance explaining monotherapy intent. Patients outside these criteria may require additional workup before the prescription is issued.

Labs Required Before Starting Ezetimibe in Louisiana

Ezetimibe does not require the same pre-treatment monitoring as a statin, but clinicians in Louisiana follow ACC/AHA guideline recommendations for baseline assessment [4].

A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) is the minimum required lab before prescribing. This panel establishes the baseline LDL-C against which treatment response will be measured at 4 to 12 weeks after initiation [4]. Most Louisiana labs (Quest, LabCorp, and hospital outpatient labs) can process a fasting lipid panel within 24 to 48 hours. Many telehealth platforms in Louisiana have partnered with these networks to allow a patient to order a lab draw before the telehealth visit.

Liver function tests (ALT, AST) are not required by the FDA label for ezetimibe alone [1], but they are commonly ordered when ezetimibe is added to a statin, since the combination product Vytorin (ezetimibe/simvastatin) carries a hepatotoxicity warning. If the patient is starting concurrent statin therapy, baseline LFTs are appropriate [4].

A thyroid-stimulating hormone (TSH) level is reasonable in patients with newly diagnosed or poorly controlled hyperlipidemia to exclude hypothyroidism as a secondary cause, per the 2022 ACC Expert Consensus Decision Pathway [12].

The 2018 ACC/AHA guideline states: "It is reasonable to measure a fasting lipid panel and, if indicated, ALT and CK before initiating statin therapy and to use these values as a reference point" [4]. That same standard applies when adding ezetimibe to existing statin therapy.

Pharmacy Access for Zetia in Louisiana

Generic ezetimibe 10 mg is stocked at virtually every major retail pharmacy in Louisiana. Cash prices vary by pharmacy and discount program.

At GoodRx pricing (verified January 2025), generic ezetimibe 10 mg (30 tablets) runs approximately $20, $28 at Walmart, Costco, and Sam's Club in Louisiana, and $28, $45 at CVS and Walgreens without a discount card [13]. Applying a GoodRx or RxSaver coupon typically reduces the price at chain pharmacies to under $30.

The Merck patient assistance program (Merck Helps) covers brand-name Zetia for patients with household incomes at or below 600% of the federal poverty level who lack prescription coverage [14]. Louisiana residents who meet that threshold and cannot afford generic ezetimibe may apply through the program at the time of prescribing.

503A compounding pharmacies in Louisiana are licensed by the Louisiana Board of Pharmacy to compound ezetimibe preparations (capsules, suspensions) for patients with documented medical needs that the commercially available tablet cannot meet, such as swallowing difficulties or confirmed tablet excipient allergies [15]. Compounded ezetimibe from a 503A pharmacy requires the same valid prescription as the commercial product and is not covered by most insurance plans, including Louisiana Medicaid.

For patients using insurance, pharmacy benefits managers typically place generic ezetimibe on tier 2 or tier 3 of commercial formularies, with copays ranging from $10, $45 per month depending on the plan [16].

Louisiana Medicaid Coverage and Prior Authorization

Louisiana Medicaid does not cover ezetimibe (brand or generic) for the hyperlipidemia adjunct indication as a standard benefit without prior authorization [17]. This is a significant barrier for the state's Medicaid population, which numbers over 2 million enrollees.

Patients whose commercial insurance requires prior authorization for ezetimibe must typically submit documentation demonstrating:

1. A baseline LDL-C above the plan's threshold (commonly 100 mg/dL or 130 mg/dL, depending on the plan).
2. A trial of at least one formulary-preferred statin at maximum tolerated dose for 90 days.
3. Documentation of inadequate LDL-C response (LDL-C still above the plan's target) or a documented statin intolerance if ezetimibe is intended as monotherapy.
4. An ASCVD risk category (high or very high) supported by a clinician note, consistent with ACC/AHA risk calculator output.

The prescribing clinician submits this documentation to the insurer through the pharmacy benefits prior authorization portal, or by fax for older Louisiana regional plans. Most decisions are returned within 72 hours for standard reviews. Urgent reviews (patient hospitalized or at imminent cardiovascular risk) are typically returned within 24 hours under Louisiana insurance regulations [18].

If the initial prior authorization is denied, an appeal supported by IMPROVE-IT trial data and ACC/AHA guideline language is frequently successful. Clinicians writing the appeal letter should cite the guideline's Class IIa, Level of Evidence B recommendation for ezetimibe in high-risk patients not at LDL-C goal on statin therapy [4].

Transferring a Zetia Prescription to Louisiana

A patient moving to Louisiana or spending extended time in the state may transfer an existing ezetimibe prescription from another state under Louisiana Board of Pharmacy rules. Because ezetimibe is not a controlled substance, a transfer is straightforward.

The receiving Louisiana pharmacy contacts the originating pharmacy directly to verify the prescription. The originating pharmacy cancels any remaining refills at its location and transfers the balance to the Louisiana pharmacy. The patient does not need a new visit for a transfer unless the original prescription has expired or has no refills remaining [19].

If refills have been exhausted, the patient needs a new encounter with a Louisiana-licensed prescriber, which may be completed via telehealth on the same day the prescription runs out. Louisiana law does not restrict the number of refills a non-controlled medication may carry, so a clinician may write a 90-day supply with up to three refills on an initial prescription if clinically appropriate [19].

Mail-order pharmacies licensed in Louisiana may also receive a transferred prescription and ship to a Louisiana address, typically offering 90-day supplies at lower per-unit cost than retail pharmacies.

Monitoring After Starting Ezetimibe

The ACC/AHA guideline recommends a repeat fasting lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy to confirm adherence and treatment response [4]. For most patients on ezetimibe 10 mg, clinicians expect a 15 to 25% reduction in LDL-C from baseline when added to a statin, or an 18 to 20% reduction as monotherapy [7].

If LDL-C remains above goal at the 12-week check, guidelines support escalation to a PCSK9 inhibitor (evolocumab or alirocumab) in very-high-risk ASCVD patients, given that ezetimibe has reached maximum dose at 10 mg [4]. PCSK9 inhibitors are available in Louisiana through specialty pharmacies with separate prior authorization pathways.

Liver function tests are not required at routine follow-up for ezetimibe monotherapy by the FDA label [1], though they may be rechecked at 3 months if a statin is co-prescribed and baseline LFTs were borderline elevated.

Blood pressure, weight, and diabetes screening should continue per standard preventive care schedules. A 2021 study in Circulation found that comprehensive LDL-C management programs that included ezetimibe as a step-therapy option reduced 10-year ASCVD event rates by an estimated 22% in high-risk patients [20].